As per the existing breast cancer guidelines, individuals diagnosed with HER2-low breast cancers continue to be classified as having HER2-negative breast cancer, for whom existing HER2-targeted therapies have not demonstrated efficacy and, thus, are not advised. Here, ERBB2 is linked to breast cancer.